{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:10:12Z","timestamp":1791274212581,"version":"4.1.0"},"reference-count":69,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>IgA nephropathy (IgAN) is an inflammatory glomerular disease caused by the production of galactose-deficient IgA1 (Gd-IgA1), which induces the formation of autoantibodies and IgA immune complexes (IgAICs) that are ultimately deposited in the mesangium. This event triggers mesangial cell proliferation, cytokine release and complement activation, and both glomerular and interstitial damage, eventually leading to kidney function decline. Persisting proteinuria is the most relevant marker of disease progression. Systemic corticosteroids (CSs), a powerful anti-inflammatory approach, have shown kidney protective effects in early trials involving patients with IgAN at risk of progression with persistent proteinuria. However, later studies raised concerns regarding severe adverse events associated with high doses of methylprednisolone and questioned the long-term benefits. As a result, the KDIGO 2021 guidelines recommended limiting CS therapy to selected patients who accepted the high risk of adverse events. The treatment landscape shifted when reduced doses of methylprednisolone, combined with Pneumocystis pneumonia prophylaxis, demonstrated similar kidney protection compared to full methylprednisolone doses with fewer adverse events. An innovative approach involves a targeted budesonide formulation acting on Peyer\u2019s patches, the main site of Gd-IgA1 production. This treatment showed benefits comparable to systemic CSs, with valuable limitations of adverse events. Several new drugs targeting key pathogenetic events of IgAN are under investigation, with promising results published in recent months. These new therapies target B cell activation (and subsequent Gd-IgA1 production), the complement cascade triggered by IgAIC deposition and the endothelin system, a key amplifier of kidney damage that contributes to the chronicity of IgAN.<\/jats:p>","DOI":"10.3390\/jcm14124045","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T05:54:05Z","timestamp":1749448445000},"page":"4045","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Treating IgA Nephropathy: Looking at the Future Without Forgetting the Past"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4713-6282","authenticated-orcid":false,"given":"Rosanna","family":"Coppo","sequence":"first","affiliation":[{"name":"Fondazione Ricerca Molinette, 10129 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,7]]},"reference":[{"key":"ref_1","first-page":"694","article-title":"Intercapillary deposits of IgA-IgG","volume":"74","author":"Berger","year":"1968","journal-title":"J. Urol. Nephrol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.amjms.2020.10.003","article-title":"IgA Nephropathy: An Interesting Autoimmune Kidney Disease","volume":"361","author":"Rajasekaran","year":"2021","journal-title":"Am. J. Med. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1002\/eji.1830191210","article-title":"Anti-inflammatory activity of human IgA antibodies and their Fab alpha fragments: Inhibition of IgG-mediated complement activation","volume":"19","author":"Russell","year":"1989","journal-title":"Eur. J. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1056\/NEJMra1206793","article-title":"IgA nephropathy","volume":"368","author":"Wyatt","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"151569","DOI":"10.1016\/j.semnephrol.2025.151569","article-title":"IgAN Across the Age Spectrum: The Pediatric Perspective","volume":"44","author":"Peruzzi","year":"2024","journal-title":"Semin. Nephrol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/ndt\/gfg207","article-title":"A tricontinental view of IgA nephropathy","volume":"18","author":"Geddes","year":"2003","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1001\/jamainternmed.2019.0600","article-title":"Evaluating a New International Risk-Prediction Tool in IgA Nephropathy","volume":"179","author":"Barbour","year":"2019","journal-title":"JAMA Intern. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","article-title":"Long-Term Outcomes in IgA Nephropathy","volume":"18","author":"Pitcher","year":"2023","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.kint.2020.10.033","article-title":"International IgA Nephropathy Network. Updating the International IgA Nephropathy Prediction Tool for use in children","volume":"99","author":"Barbour","year":"2021","journal-title":"Kidney Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/ckj\/sfaa060","article-title":"Recurrence of immunoglobulin A nephropathy after kidney transplantation: A narrative review of the incidence, risk factors, pathophysiology and management of immunosuppressive therapy","volume":"13","author":"Infante","year":"2020","journal-title":"Clin. Kidney J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1681\/ASN.2011050464","article-title":"The pathophysiology of IgA nephropathy","volume":"22","author":"Suzuki","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1016\/j.ekir.2023.09.020","article-title":"Evaluating Progression Risk in Patients With Immunoglobulin A Nephropathy","volume":"8","author":"Cattran","year":"2023","journal-title":"Kidney Int. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0140-6736(98)03563-6","article-title":"Corticosteroids in IgA nephropathy: A randomised controlled trial","volume":"353","author":"Pozzi","year":"1999","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1093\/ndt\/gfp356","article-title":"Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy","volume":"24","author":"Manno","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1053\/j.ajkd.2008.07.029","article-title":"Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: A randomized controlled trial","volume":"53","author":"Lv","year":"2009","journal-title":"Am. J. Kidney Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"STOP-IgAN Investigators. Intensive Supportive Care plus Immunosuppression in IgA Nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2017.9362","article-title":"TESTING Study Group. Effect of Oral Methylprednisolone on Clinical Outcomes in Patients with IgA Nephropathy: The TESTING Randomized Clinical Trial","volume":"318","author":"Lv","year":"2017","journal-title":"JAMA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/nrneph.2013.59","article-title":"Treatment of IgA nephropathy and Henoch-Sch\u00f6nlein nephritis","volume":"9","author":"Floege","year":"2013","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1001\/jama.2022.5368","article-title":"TESTING Study Group. Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial","volume":"327","author":"Lv","year":"2022","journal-title":"JAMA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.kint.2022.09.017","article-title":"NefIgArd Trial Investigators. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy","volume":"103","author":"Barratt","year":"2023","journal-title":"Kidney Int."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"NefIgArd trial investigators. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/01.ASN.0000103869.08096.4F","article-title":"Corticosteroid effectiveness in IgA nephropathy: Long-term results of a randomized, controlled trial","volume":"15","author":"Pozzi","year":"2004","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_23","first-page":"1","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis","volume":"2","author":"Cattran","year":"2012","journal-title":"Kidney Int. Suppl."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.kint.2020.04.046","article-title":"STOP-IgAN Investigators. After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy","volume":"98","author":"Rauen","year":"2020","journal-title":"Kidney Int."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"ii40","DOI":"10.1093\/ckj\/sfad224","article-title":"Systemic and targeted steroids for the treatment of IgA nephropathy","volume":"16","author":"Locatelli","year":"2023","journal-title":"Clin. Kidney J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1080\/01926230600865531","article-title":"Normal structure, function, and histology of mucosa-associated lymphoid tissue","volume":"34","author":"Cesta","year":"2006","journal-title":"Toxicol Pathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/j.ekir.2020.08.009","article-title":"Why Target the Gut to Treat IgA Nephropathy?","volume":"5","author":"Barratt","year":"2020","journal-title":"Kidney Int. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/0022-4731(82)90035-8","article-title":"Influence of 16 alpha, 17 alpha-acetal substitution and steroid nucleus fluorination on the topical to systemic activity ratio of glucocorticoids","volume":"16","author":"Brattsand","year":"1982","journal-title":"J. Steroid Biochem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1007\/s00467-025-06725-1","article-title":"Expected and verified benefits from old and new corticosteroid treatments in IgA nephropathy: From trials in adults to new IPNA-KDIGO guidelines","volume":"40","author":"Peruzzi","year":"2025","journal-title":"Pediatr. Nephrol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/ki.2014.63","article-title":"VALIGA study of the ERA-EDTA Immunonephrology Working Group. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments","volume":"86","author":"Coppo","year":"2014","journal-title":"Kidney Int."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s00281-021-00871-y","article-title":"The mucosal immune system and IgA nephropathy","volume":"43","author":"Gesualdo","year":"2021","journal-title":"Semin. Immunopathol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1093\/ndt\/gfu343","article-title":"The intestine-renal connection in IgA nephropathy","volume":"30","author":"Coppo","year":"2015","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.kint.2023.11.003","article-title":"Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: Insights from the NEFIGAN trial","volume":"105","author":"Wimbury","year":"2024","journal-title":"Kidney Int."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1146\/annurev-immunol-030409-101314","article-title":"Adaptive immune regulation in the gut: T cell-dependent and T cell-independent IgA synthesis","volume":"28","author":"Fagarasan","year":"2010","journal-title":"Annu. Rev. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Cheung, C.K., Barratt, J., Liew, A., Zhang, H., Tesar, V., and Lafayette, R. (2024). The role of BAFF and APRIL in IgA nephropathy: Pathogenic mechanisms and targeted therapies. Front. Nephrol., 3.","DOI":"10.3389\/fneph.2023.1346769"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e3099","DOI":"10.1097\/MD.0000000000003099","article-title":"Increased APRIL Expression Induces IgA1 Aberrant Glycosylation in IgA Nephropathy","volume":"95","author":"Zhai","year":"2016","journal-title":"Medicine"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"16001","DOI":"10.1038\/nrdp.2016.1","article-title":"IgA nephropathy","volume":"2","author":"Lai","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1053\/j.ajkd.2016.11.027","article-title":"Mycophenolate Mofetil Combined With Prednisone Versus Full-Dose Prednisone in IgA Nephropathy With Active Proliferative Lesions: A Randomized Controlled Trial","volume":"69","author":"Hou","year":"2017","journal-title":"Am. J. Kidney Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e2254054","DOI":"10.1001\/jamanetworkopen.2022.54054","article-title":"Effectiveness of Mycophenolate Mofetil Among Patients With Progressive IgA Nephropathy: A Randomized Clinical Trial","volume":"6","author":"Hou","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_41","first-page":"1186","article-title":"Immunosuppression versus Supportive Care on Kidney Outcomes in IgA Nephropathy in the Real-World Setting","volume":"18","author":"Zhao","year":"2023","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ekir.2023.10.015","article-title":"Mycophenolate Mofetil and Steroid for Treatment of Patients With IgA Nephropathy","volume":"9","author":"Miao","year":"2023","journal-title":"Kidney Int. Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1681\/ASN.2016060640","article-title":"A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction","volume":"28","author":"Lafayette","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/nyas.13577","article-title":"Efficient long-term depletion of CD20+ B cells by rituximab does not affect gut-resident plasma cells","volume":"1415","author":"Uzzan","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Maixnerova, D., El Mehdi, D., Rizk, D.V., Zhang, H., and Tesar, V. (2022). New treatment strategies for IgA nephropathy: Targeting plasma cells as the main source of pathogenic antibodies. Clin. Med., 11.","DOI":"10.3390\/jcm11102810"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"gfae069-0139","DOI":"10.1093\/ndt\/gfae069.139","article-title":"Felzartamab (anti-CD38) in patients with IgA Nephropathy: Interim results from the IGNAZ study (abstract)","volume":"39","author":"Floege","year":"2024","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2305635","article-title":"ENVISION Trial Investigators Group. A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy","volume":"390","author":"Mathur","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/j.ekir.2022.01.121","article-title":"POS-109 Interim results of phase 1 and 2 trials to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of BION-1301 in patients with IgA nephropathy","volume":"7","author":"Barratt","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.kint.2024.03.012","article-title":"A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy","volume":"105","author":"Lafayette","year":"2024","journal-title":"Kidney Int."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1681\/ASN.0000000541","article-title":"ORIGIN Phase 2b Investigators. Long-Term Results from an Open-Label Extension Study of Atacicept for the Treatment of IgA Nephropathy","volume":"36","author":"Barratt","year":"2025","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","article-title":"Randomized Phase 2 Trial of Telitacicept in Patients with IgA Nephropathy with Persistent Proteinuria","volume":"8","author":"Lv","year":"2023","journal-title":"Kidney Int. Rep."},{"key":"ref_52","first-page":"FRPO854","article-title":"Results from longer follow-up with povetacicept, an enhanced dual BAFF\/APRIL antagonist, in IgA nephropathy (RUBY-3 study)","volume":"35","author":"Madan","year":"2024","journal-title":"J. Am. Soc. Nephrol. Abstr."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"ii28","DOI":"10.1093\/ckj\/sfad198","article-title":"Targeting complement in IgA nephropathy","volume":"16","author":"Sevillano","year":"2023","journal-title":"Clin. Kidney J."},{"key":"ref_54","first-page":"123","article-title":"IgA nephropathy","volume":"76","author":"McCoy","year":"1974","journal-title":"Am. J. Pathol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.kint.2023.09.027","article-title":"Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy","volume":"105","author":"Zhang","year":"2024","journal-title":"Kidney Int."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2410316","article-title":"Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy","volume":"392","author":"Perkovic","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2215\/CJN.0000000000000384","article-title":"Cemdisiran Phase 2 Study Investigators and Collaborators. Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy: A Randomized Controlled Trial","volume":"19","author":"Barratt","year":"2024","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1681\/ASN.0000000534","article-title":"SANCTUARY Study Investigators. Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial","volume":"36","author":"Lafayette","year":"2025","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"DAPA-CKD Trial Committees and Investigators. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/S0140-6736(23)00569-X","article-title":"PROTECT Investigators. Sparsentan in patients with IgA nephropathy: A prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial","volume":"401","author":"Heerspink","year":"2023","journal-title":"Lancet"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"DUPRO steering committee and PROTECT Investigators. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Rovin","year":"2023","journal-title":"Lancet"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2409415","article-title":"ALIGN Study Investigators. Atrasentan in Patients with IgA Nephropathy","volume":"392","author":"Heerspink","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_63","first-page":"544","article-title":"The Selective Endothelin Receptor Antagonist SC0062 in IgA Nephropathy: A Randomized Double-Blind Placebo-Controlled Clinical Trial","volume":"392","author":"Heerspink","year":"2025","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Tang, C., Si, F.L., Chen, P., Hou, W.Y., Yang, H.Y., Lv, J.C., Shi, S.F., Zhou, X.J., Liu, L.J., and Zhang, H. (J. Nephrol., 2025). Effectiveness and safety of finerenone in non-diabetic patients with IgA nephropathy, J. Nephrol., ahead of print.","DOI":"10.1007\/s40620-025-02240-6"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/ndt\/gfae132","article-title":"Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial","volume":"40","author":"Heerspink","year":"2025","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1681\/ASN.0000000000000242","article-title":"Treatment of IgA Nephropathy: A Rapidly Evolving Field","volume":"35","author":"Fervenza","year":"2024","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.kint.2025.01.014","article-title":"Treatment of patients with IgA nephropathy: A call for a new paradigm","volume":"107","author":"Floege","year":"2025","journal-title":"Kidney Int."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40620-024-02071-x","article-title":"Italian Group of Steroids in IgAN. The safety of corticosteroid therapy in IGA nephropathy: Analysis of a real-life Italian cohort","volume":"38","author":"Baragetti","year":"2025","journal-title":"J. Nephrol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e27778","DOI":"10.1097\/MD.0000000000027778","article-title":"Comparison of administration of single- and triple-course steroid pulse therapy combined with tonsillectomy for immunoglobulin A nephropathy","volume":"100","author":"Nakazawa","year":"2021","journal-title":"Medicine"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/12\/4045\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:48:22Z","timestamp":1760032102000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/12\/4045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,7]]},"references-count":69,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["jcm14124045"],"URL":"https:\/\/doi.org\/10.3390\/jcm14124045","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,7]]}}}